Published in Emerg Infect Dis on April 01, 2004
Primary pneumocystis infection in infants hospitalized with acute respiratory tract infection. Emerg Infect Dis (2007) 1.05
Possible nosocomial transmission of Pneumocystis jirovecii. Emerg Infect Dis (2012) 0.84
Prospective multicenter study of Pneumocystis jirovecii colonization among cystic fibrosis patients in France. J Clin Microbiol (2012) 0.83
Colonization of Pneumocystis jirovecii in Chronic Obstructive Pulmonary Disease (COPD) patients and the rate of Pneumocystis pneumonia in Iranian non-HIV(+) immunocompromised patients. Iran J Microbiol (2013) 0.80
Co-infection of Mycobacterium tuberculosis and Pneumocystis jirovecii in the Iranian Patients With Human Immunodeficiency Virus. Jundishapur J Microbiol (2015) 0.78
Pneumocystis jirovecii--from a commensal to pathogen: clinical and diagnostic review. Parasitol Res (2015) 0.77
High prevalence of Pneumocystis jirovecii dihydropteroate synthase gene mutations in patients with first episode of Pneumocystis pneumonia in Santiago, Chile, and their clinical response to trimethoprim-sulfamethoxazole therapy. Antimicrob Agents Chemother (2016) 0.75
Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet (1999) 2.80
Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis (2001) 2.24
1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Recomm Rep (1999) 2.15
Genetic variation in Pneumocystis carinii isolates from different geographic regions: implications for transmission. Emerg Infect Dis (2000) 2.08
Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis (1999) 1.79
Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis (2000) 1.63
Dihydropteroate synthase polymorphisms in Pneumocystis carinii. J Infect Dis (1997) 1.60
Pneumocystis carinii carriage in immunocompetent patients with primary pulmonary disorders as detected by single or nested PCR. J Clin Microbiol (1999) 1.58
Transmission of Pneumocystis carinii disease from immunocompetent contacts of infected hosts to susceptible hosts. Eur J Clin Microbiol Infect Dis (2000) 1.55
Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping. QJM (1998) 1.54
Rapid detection of dihydropteroate polymorphism in AIDS-related Pneumocystis carinii pneumonia by restriction fragment length polymorphism. Scand J Infect Dis (2000) 1.50
Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J Clin Microbiol (2001) 1.47
Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS (1998) 1.44
Sulfa or sulfone prophylaxis and geographic region predict mutations in the Pneumocystis carinii dihydropteroate synthase gene. J Infect Dis (2000) 1.41
Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study. Lancet (2001) 1.23
Probable mother-to-infant transmission of Pneumocystis carinii f. sp. hominis infection. J Clin Microbiol (2002) 1.22
Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene. Lancet (1998) 1.20
Limited asymptomatic carriage of Pneumocystis jiroveci in human immunodeficiency virus-infected patients. J Infect Dis (2003) 1.17
Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency virus-positive and -negative patients. J Infect Dis (2003) 1.15
Relationship between mutations in dihydropteroate synthase of Pneumocystis carinii f. sp. hominis isolates in Japan and resistance to sulfonamide therapy. J Clin Microbiol (2000) 1.12
Pneumocystis carinii f. sp. hominis is not infectious for SCID mice. J Clin Microbiol (2002) 1.12
Pneumocystis carinii colonization in the absence of immunosuppression. Scand J Infect Dis (1997) 1.12
Phylogeny of Pneumocystis carinii from 18 primate species confirms host specificity and suggests coevolution. J Clin Microbiol (2001) 1.08
Genotypes at the internal transcribed spacers of the nuclear rRNA operon of Pneumocystis jiroveci in nonimmunosuppressed infants without severe pneumonia. J Clin Microbiol (2003) 1.06
Pulmonary colonization with Pneumocystis carinii in human immunodeficiency virus-negative patients: assessing risk with blood CD4+ T cell counts. Clin Infect Dis (1999) 1.06
Pneumocystis carinii detection using nested-PCR in nasopharyngeal aspirates of immunocompetent infants with bronchiolitis. J Eukaryot Microbiol (2001) 1.02
Mutations in the dihydropteroate synthase gene of human-derived Pneumocystis carinii isolates from Italy are infrequent but correlate with prior sulfa prophylaxis. J Infect Dis (2002) 0.99
Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in immunocompromised patients. Microbes Infect (2000) 0.99
Mutations in dihydropteroate synthase gene of Pneumocystis carinii in HIV patients with Pneumocystis carinii pneumonia. Int J Antimicrob Agents (2001) 0.96
Drug-resistant Pneumocystis carinii. Lancet (1999) 0.95
Genotypes of Pneumocystis jiroveci isolates obtained in Harare, Zimbabwe, and London, United Kingdom. Antimicrob Agents Chemother (2003) 0.94
Rapid detection of mutations in the human-derived Pneumocystis carinii dihydropteroate synthase gene associated with sulfa resistance. Antimicrob Agents Chemother (2001) 0.88
Pneumocystis jirovecii dihydropteroate synthase genotypes in French patients with pneumocystosis: a 1998-2001 prospective study. Med Mycol (2003) 0.87
Pneumocystis carinii dihydropteroate synthase genotypes in HIV-infected persons residing in San Francisco: possible implications for disease transmission. J Eukaryot Microbiol (2001) 0.84
Pneumocystis carinii dihydropteroate synthase mutations and treatment with sulfa or sulfone regimens: a proposal for standardized definitions for clinical evaluation. J Eukaryot Microbiol (2001) 0.80
Contribution of dihydropteroate synthase gene typing for Pneumocystis carinii f.sp. hominis epidemiology. J Eukaryot Microbiol (1999) 0.77
Genotype of 88 Toxoplasma gondii isolates associated with toxoplasmosis in immunocompromised patients and correlation with clinical findings. J Infect Dis (2009) 2.33
Does using pressure-controlled ventilation to rest respiratory muscles improve sleep in ICU patients? Respir Med (2013) 2.01
Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clin Infect Dis (2010) 1.41
Antibodies to tetanus, diphtheria and pertussis among healthy adults vaccinated according to the French vaccination recommendations. Hum Vaccin (2009) 1.14
Strain typing methods and molecular epidemiology of Pneumocystis pneumonia. Emerg Infect Dis (2004) 1.12
A cluster of Pneumocystis infections among renal transplant recipients: molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii. Clin Infect Dis (2012) 1.10
Genotypes at the internal transcribed spacers of the nuclear rRNA operon of Pneumocystis jiroveci in nonimmunosuppressed infants without severe pneumonia. J Clin Microbiol (2003) 1.06
Assist-control ventilation vs. low levels of pressure support ventilation on sleep quality in intubated ICU patients. Intensive Care Med (2007) 0.99
Real time quantitative PCR assay for Pneumocystis jirovecii detection. J Eukaryot Microbiol (2003) 0.97
[Human cryptosporidiosis and Cryptosporidium spp. in Haiti]. Trop Med Int Health (2006) 0.94
Apparent absence of Pneumocystis jirovecii in healthy subjects. Clin Infect Dis (2006) 0.94
Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000-2011. Malar J (2013) 0.93
Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1->3)-β-D-glucan for differential diagnosis of pneumocystis pneumonia and Pneumocystis colonization. J Clin Microbiol (2013) 0.93
Pneumocystis jiroveci internal transcribed spacer types in patients colonized by the fungus and in patients with pneumocystosis from the same French geographic region. J Clin Microbiol (2003) 0.93
Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis (2014) 0.92
Multimodal treatment of thymic carcinoma: Report of nine cases. Lung Cancer (2007) 0.92
In vivo probe-based confocal laser endomicroscopy in amiodarone-related pneumonia. Eur Respir J (2012) 0.92
Longevity effect of IGF-1R(+/-) mutation depends on genetic background-specific receptor activation. Aging Cell (2013) 0.91
Bacterial infection profiles in lung cancer patients with febrile neutropenia. BMC Infect Dis (2011) 0.89
Similar genotypes of Pneumocystis jirovecii in different forms of Pneumocystis infection. Microbiology (2004) 0.87
Admission of advanced lung cancer patients to intensive care unit: a retrospective study of 76 patients. BMC Cancer (2011) 0.87
Immunocompetent infants as a human reservoir for Pneumocystis jirovecii: rapid screening by non-invasive sampling and real-time PCR at the mitochondrial large subunit rRNA gene. J Eukaryot Microbiol (2003) 0.86
Possible nosocomial transmission of Pneumocystis jirovecii. Emerg Infect Dis (2012) 0.84
Pneumocystis jirovecii genotypes involved in pneumocystis pneumonia outbreaks among renal transplant recipients. Clin Infect Dis (2012) 0.83
Serum (1->3)-beta-D-glucan levels in primary infection and pulmonary colonization with Pneumocystis jirovecii. J Clin Microbiol (2011) 0.83
Candidal abscess of the parotid gland due to Candida glabrata: report of a case and literature review. Med Mycol (2010) 0.81
Respiratory-gated 18F-FDG PET imaging in lung cancer: effects on sensitivity and specificity. Acta Radiol (2011) 0.80
Pneumocystis jirovecii and cystic fibrosis in France. Scand J Infect Dis (2010) 0.80
Pneumocystis jiroveci genotypes and primary infection. Clin Infect Dis (2003) 0.80
Non-tuberculous mycobacteria pulmonary infection: management and follow-up of 31 infected patients. J Infect (2007) 0.79
Comparison of 2 maintenance doses (100 microg vs 200 microg) in Hymenoptera venom immunotherapy: influence of the maintenance dose on the immunologic response. Ann Allergy Asthma Immunol (2005) 0.79
Hypothetical Pneumocystis jirovecii transmission from immunocompetent carriers to infant. Emerg Infect Dis (2009) 0.78
Use of denaturing high-performance liquid chromatography (DHPLC) to characterize the bacterial and fungal airway microbiota of cystic fibrosis patients. J Microbiol (2014) 0.78
Multilocus genotyping of Pneumocystis jirovecii in patients developing diverse forms of parasitism: implication for a wide human reservoir for the fungus. J Eukaryot Microbiol (2003) 0.77
Effects of intermittent negative pressure ventilation on effective ventilation in normal awake subjects. Chest (2002) 0.77
Pneumocystosis: survey and DHPS genotype analysis in 14 Parisian hospitals in 2003 and 2004. J Eukaryot Microbiol (2006) 0.77
Pneumocystis jirovecii genotypes in European patients with chronic obstructive pulmonary diseases. J Eukaryot Microbiol (2006) 0.76
Evaluation of fungal aerosols using Temporal Temperature Gradient Electrophoresis (TTGE) and comparison with culture. J Microbiol Methods (2007) 0.76
Development of a real-time PCR-based fluorescence assay for rapid detection of point mutations in Pneumocystis jirovecii dihydropteroate synthase gene. J Eukaryot Microbiol (2003) 0.76
Disrupted sleep during mechanical ventilation. Am J Respir Crit Care Med (2003) 0.75
Severe Pneumocystis pneumonia in a renal transplant recipient after long term mycophenolate mofetil treatment. Rev Inst Med Trop Sao Paulo (2005) 0.75
Acknowledging previous work is part of scientific process. Am J Respir Crit Care Med (2004) 0.75
Circulation of Pneumocystis dihydropteroate synthase mutants in France. Diagn Microbiol Infect Dis (2012) 0.75
Pneumocystis jirovecii haplotypes at the internal transcribed spacers of the rRNA operon in French HIV-negative patients with diverse clinical presentations of Pneumocystis infections. Med Mycol (2013) 0.75
Photo quiz: A 39-year-old man with human immunodeficiency virus infection presenting with an alveolo-interstitial pulmonary syndrome. J Clin Microbiol (2013) 0.75
Molecular typing of Pneumocystis jirovecii in a patient from French Guiana. Mycoses (2010) 0.75
Positron emission tomography-based evidence of low-amplitude respiratory motion in patients with chronic obstructive pulmonary disease. Ann Nucl Med (2015) 0.75
[Occupational lipid pneumonia induced by cutting fluids exposition]. Presse Med (2011) 0.75
[Lemierre syndrome: unusual, but still possible]. Ann Med Interne (Paris) (2003) 0.75
Absence of Pneumocystis dihydropteroate synthase mutants in Brittany, France. Diagn Microbiol Infect Dis (2013) 0.75
Invasive Infections with Nannizziopsis obscura Species Complex in 9 Patients from West Africa, France, 2004-2020. Emerg Infect Dis (2020) 0.75